Allscripts announces fourth quarter and 2016 full-year results

Go back to Allscripts announces fourth quarter and 2016 full-year results

Jefferies Reiterates Buy on Allscripts (MDRX) Following 4Q

February 17, 2017 8:26 AM EST

Jefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following 4Q earnings report. MDRX reported EPS of $0.14, which compares to $0.15 for consensus. Downside was driven by higher SG&A, partially offset by better revenue, a higher gross margin and... More

Allscripts (MDRX) Misses Q4 EPS by 1c, Offers Guidnce

February 16, 2017 4:05 PM EST

Allscripts (NASDAQ: MDRX) reported Q4 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $429.4 million versus the consensus estimate of $424.11 million.

2017 Financial Outlook

Allscripts affirms the following financial outlook for 2017, published originally on January 9, 2017:

Non-GAAP revenue of... More